Aptose Biosciences’ (APTO) Buy Rating Reaffirmed at Canaccord Genuity
Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS)‘s stock had its “buy” rating reaffirmed by analysts at Canaccord Genuity in a note issued to investors on Friday. They currently have a $7.00 price objective on the biotechnology company’s stock.
The analysts wrote, “CATB reported 3/31 cash of $38.5MM, sufficient to fund operations into Q2:18.””
Shares of Aptose Biosciences (NASDAQ:APTO) remained flat at $1.08 on Friday. The company’s stock had a trading volume of 173,656 shares. The firm’s market cap is $20.36 million. Aptose Biosciences has a one year low of $0.78 and a one year high of $4.30. The stock has a 50 day moving average of $1.02 and a 200-day moving average of $1.10.
COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/12/aptose-biosciences-inc-apto-receives-buy-rating-from-canaccord-genuity.html.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Baker BROS. Advisors LP acquired a new position in Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 404,211 shares of the biotechnology company’s stock, valued at approximately $909,000. Baker BROS. Advisors LP owned approximately 3.14% of Aptose Biosciences as of its most recent filing with the SEC. 18.42% of the stock is currently owned by institutional investors and hedge funds.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.